CD27 and in situ carcinoma: CD27 is a T-cell activation marker, whose soluble form has been shown by others to be significantly elevated in people with multiple sclerosis [32], and predictive of future multiple sclerosis disease activity [33], including transition from CIS to multiple sclerosis [34].